Savient Pharmaceuticals Inc., in Bridgewater, announced today it is partnering with Sobi, of Stockholm, to promote Kineret, a treatment for rheumatoid arthritis, in the United States.
Savient is a specialty biopharmaceutical company that has developed and commercialized the gout treatment Krystexxa, which it continues to market.
According to the announcement, Sobi has granted Savient the exclusive rights to co-promote the sale of Kineret with Sobi in the United States. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety and regulatory activities.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy